Literature DB >> 10456904

Assessment of immunity to mycobacterial infection with luciferase reporter constructs.

V A Snewin1, M P Gares, P O Gaora, Z Hasan, I N Brown, D B Young.   

Abstract

Protective immunity to mycobacterial infection is incompletely understood but probably involves the coordinated interaction of multiple cell types and cytokines. With the aim of developing assays that might provide a surrogate measure of protective immunity, we have investigated the use of recombinant mycobacteria carrying luciferase reporter enzymes to assess the effectiveness of antimycobacterial immunity in model systems. Measurement of luminescence was shown to provide a rapid and simple alternative to the counting of CFU as a means of monitoring mycobacterial viability. We describe optimization of a luciferase reporter strain of Mycobacterium tuberculosis and demonstrate its application for the study of mycobacterial interactions with host cells in tissue culture and the rapid assessment of vaccine efficacy in a murine model.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10456904      PMCID： PMC96782          DOI： 10.1128/IAI.67.9.4586-4593.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  26 in total

1.  Reporter gene technology to assess activity of antimycobacterial agents in macrophages.

Authors:  T M Arain; A E Resconi; D C Singh; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery.

Authors:  T M Arain; A E Resconi; M J Hickey; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Protection against mycoplasma infection using expression-library immunization.

Authors:  M A Barry; W C Lai; S A Johnston
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

Review 4.  Use of lux genes in applied biochemistry.

Authors:  P J Hill; G S Stewart
Journal:  J Biolumin Chemilumin       Date:  1994 May-Jun

5.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.

Authors:  K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; I M Orme; S Baldwin; C D'Souza; A Drowart; E Lozes; P Vandenbussche; J P Van Vooren; M A Liu; J B Ulmer
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Vaccination against tuberculosis by DNA injection.

Authors:  R E Tascon; M J Colston; S Ragno; E Stavropoulos; D Gregory; D B Lowrie
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

7.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.

Authors:  M C Raviglione; D E Snider; A Kochi
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

8.  Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents.

Authors:  P W Andrew; I S Roberts
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

9.  Transformation of mycobacterial species using hygromycin resistance as selectable marker.

Authors:  T R Garbe; J Barathi; S Barnini; Y Zhang; C Abou-Zeid; D Tang; R Mukherjee; D B Young
Journal:  Microbiology       Date:  1994-01       Impact factor: 2.777

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962
View more
  83 in total

1.  The stringent response of Mycobacterium tuberculosis is required for long-term survival.

Authors:  T P Primm; S J Andersen; V Mizrahi; D Avarbock; H Rubin; C E Barry
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

2.  The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages.

Authors:  J J De Voss; K Rutter; B G Schroeder; H Su; Y Zhu; C E Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines.

Authors:  Sushila D'Souza; Marta Romano; Johanna Korf; Xiao-Ming Wang; Pierre-Yves Adnet; Kris Huygen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 4.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.

Authors:  Tianyu Zhang; Si-Yang Li; Paul J Converse; Deepak V Almeida; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

6.  Chemical modification of capuramycins to enhance antibacterial activity.

Authors:  Elena Bogatcheva; Tia Dubuisson; Marina Protopopova; Leo Einck; Carol A Nacy; Venkata M Reddy
Journal:  J Antimicrob Chemother       Date:  2010-12-23       Impact factor: 5.790

7.  Alternative luciferase for monitoring bacterial cells under adverse conditions.

Authors:  Siouxsie Wiles; Kathryn Ferguson; Martha Stefanidou; Douglas B Young; Brian D Robertson
Journal:  Appl Environ Microbiol       Date:  2005-07       Impact factor: 4.792

8.  In vitro antimycobacterial activities of capuramycin analogues.

Authors:  Venkata M Reddy; Leo Einck; Carol A Nacy
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

9.  Evolution of the mycobacterial SigK regulon.

Authors:  Frédéric Veyrier; Battouli Saïd-Salim; Marcel A Behr
Journal:  J Bacteriol       Date:  2008-01-18       Impact factor: 3.490

10.  Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

Authors:  Frank A W Verreck; Tjitske de Boer; Dennis M L Langenberg; Marieke A Hoeve; Matthijs Kramer; Elena Vaisberg; Robert Kastelein; Arend Kolk; René de Waal-Malefyt; Tom H M Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.